In the News


- Home
- Investor & Media
- In the News
Recce Pharmaceuticals Ltd attracts $1.8 million as it moves toward human clinical trials Recce Pharmaceuticals Ltd (ASX:RCE) has raised about $1.8 million from sophisticated and institutional investors...
In US patent for synthetic antibiotic to target growing superbug problem Recce Pharmaceuticals (ASX: RCE) has locked-in a US patent for its broad-spectrum synthetic antibiotics, paving the way for the...
A millennial director put his $100k into his own company rather than a house deposit It was millionaire’s row last week in small cap land, with four multi-million dollar trades and one that was pretty close...
The biotech veteran chasing a billion-dollar pot of gold He was famously worth over $130 million — on paper at least — when he was running Chemeq, which blew itsel up a decade ago after he left.
Why this 29-year-old investor took a six-figure stake in a $17m biotech company I prefer to have my money be working for me,” he tells Stockhead. “I don’t want it to be at the beck and call of Trump having...
Interview with Peter Switzer One of the worrying trends in hospitals are superbugs, raising question marks over the efficacy of antibiotics. Listed company Recce target is targeting this issue ..
Small companies play big role in search for superbug killers Superbugs are quickly becoming a top health concern, yet there has been a roughly 30-year dry spell in antibiotic molecule discovery...
WA tests synthetic antibiotic A Perth-based pharmaceutical research company is a step closer to developing a new class of synthetic antibiotics to overcome superbugs. Recce Limited has started ...
Australia’s Recce strives for immune-proof super-antibiotic Introductory offers to be billed as follows: The Australian Digital Subscription costs 50c per day, billed monthly (min cost up...
Recce nears clinic with ‘master key’ antibiotic to take on superbugs PERTH, Australia – A new class of synthetic antibiotics with broad-spectrum activity is being developed by Sydney-based...
The world needs new classes of antibiotics Antibiotics The world needs new classes of antibiotics Antibiotics are used as our frontline treatment...
New class of synthetic antibiotics set to tackle superbugs PERTH, Australia – A new class of synthetic antibiotics with broad-spectrum activity is being developed by Sydney-based...
Recce Pharmaceuticals is among dozens of WA-founded biotech companies that are making serious waves in the medical research sector, with COVID-19 the latest disease in its sights...
A revolutionary approach to medicine: synthetic anti-Infectives Anti-infectives are used as our frontline treatment for everyday and life threatening bacteria and viral infections…
AMR is a ticking time bomb argues Recce CEO James Graham...
Click here for full Press Release and Presentation
A NEW CLASS OF ANTIBIOTICS
ADVANCING THE ‘ARMS RACE’ against antibiotic-resistant superbugs
James Graham, CEO of Recce Pharmaceuticals shared his views on the multiple patient dosing in P-I/II clinical trial of RECCE 327 (R327) for the treatment of infected burn wounds.
A REVOLUTIONARY APPROACH against antimicrobial resistance
Recce listed on the Frankfurt Stock Exchange and is working with German asset manager DGWA as it embarks on a global superbug-fighting strategy.
Recce listed on the Frankfurt Stock Exchange and is working with German asset manager DGWA as it embarks on a global superbug-fighting strategy.
Recce Pharmaceuticals is working on a solution.